umifenovir (arbidol) - living meta-analysis of clinical studies

table network network 2

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

	COVID 19 all comers	COVID-19 mild to moderate

	COVID 19 hospitalized	COVID 19 all comers	COVID-19 mild to moderate
umifenovir (arbidol)	UAIIC Nojomi	ELACOI ...	Yethindra ELACOI ...

1 studies excluded by filtering options 1

6750

Chen_arbidol, 2020

1

13

4

not a RCT

high risk of bias